Lutetium[177Lu] Oxodotreotide Injection

DRUG3 trials

Sponsors

Sinotau Pharmaceutical Group, Peking University

Conditions

Advanced Neuroendocrine NeoplasmNeuroendocrine Tumors

Phase 2

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Not yet recruitingNCT05894486

Peking UniversityNeuroendocrine Tumors

Start: 2023-06-05End: 2026-06-05Target: 40Updated: 2023-06-08

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Active, not recruitingNCT06398444

Sinotau Pharmaceutical GroupAdvanced Neuroendocrine Neoplasm

Start: 2024-06-11End: 2029-06-01Target: 74Updated: 2025-09-05

Phase 3

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Active, not recruitingNCT05459844

Sinotau Pharmaceutical GroupNeuroendocrine Tumors

Start: 2022-08-31End: 2028-12-31Updated: 2025-09-05

Related Papers

Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE.

2026-02-25

Radiation exposure and protection advice after [<sup>177</sup>Lu]Lu-DOTA-TATE therapy in China.

2024-11-281 citations